Condition category
Circulatory System
Date applied
Date assigned
Last edited
Retrospectively registered
Overall trial status
Recruitment status
No longer recruiting

Plain English Summary

Background and study aims
Varicose veins are a common condition, in which the veins (usually on the legs) become swollen and enlarged. It happens when the small valves inside the veins which are designed to make sure blood is travelling in the right direction (back towards the heart) stop working properly, causing blood to leak backwards and collect in the vein. Over the past decade, new minimally invasive treatments (‘key hole’ procedures) have been introduced. A common type of procedure used is ultrasound guided foam sclerotherapy. This is where special foam is injected into the veins (a process guided using ultrasound scanning) which seal the damage veins closed. This type of procedure is becoming more and more popular as they are associated with fewer complications and a quicker recovery than traditional surgery (to remove the veins). Despite advances in surgical techniques, there is still uncertainty as to the role of compression therapy (wearing tight stockings which squeeze the leg to improve circulation) in the management of varicose veins. The American Venous Forum (an American veins organisation) recommends the use of compression stockings to reduce the risk of clot (haematoma) formation, pain and swelling. The NICE Guidelines have recommended further research into the use of compression stockings as post-procedure intervention because of this lack of evidence. The aim of this study is to compare the effect of compression therapy following foam sclerotherapy.

Who can participate?
Adults with varicose veins suitable for foam sclerotherapy.

What does the study involve?
Participants in both groups undergo foam sclerotherapy of their varicose veins, before being randomly allocated to one of two groups. Those in the first group wear bandages for 24 hours and receive no compression therapy. Those in the second group are asked to wear compression stockings for 1 week following foam sclerotherapy. All participants are given a diary card to rate their pain levels every day for 10 days after their surgery. They are then received two weeks after the procedure in order to fill in questionnaires about their quality of life and undergo a physical examination to see if there is there is any skin discolouration or inflammation present. Six months after the procedure, participants attend another clinic appointment where they have an ultrasound scan to find out if the surgery has worked and fill in further questionnaires.

What are the possible benefits and risks of participating?
Not provided at time of registration

Where is the study run from?
Charing Cross Hospital (UK)

When is the study starting and how long is it expected to run for?
June 2015 to December 2017

Who is funding the study?
Chemische Fabrik Kreussler & Co. GmbH (Germany)

Who is the main contact?
Mr Roshan Bootun

Trial website

Contact information



Primary contact

Mr Roshan Bootun


Contact details

Vascular Research Office
Floor 4 North
Charing Cross Hospital
Imperial College London
Fulham Palace Road
W6 8RF
United Kingdom
+44 20 3311 7335

Additional identifiers

EudraCT number number

Protocol/serial number


Study information

Scientific title

A randomised controlled trial of compression therapy following foam sclerotherapy of varicose veins


Study hypothesis

Compression therapy following foam sclerotherapy more effective than foam sclerotherapy alone.

Ethics approval

National Research Ethics Service (NRES) Committee North East - Newcastle & North Tyneside 1, 09/09/2015, ref: 15/NE/0314

Study design

Randomised; Interventional; Design type: Treatment, Device

Primary study design


Secondary study design

Randomised controlled trial

Trial setting

Not specified

Trial type


Patient information sheet

Not available in web format, please use the contact details below to request a patient information sheet


Varicose veins


Patients will be randomised to have compression (group A) or no compression (group B). This will be done by using an online randomisation software (Sealed Envelope Ltd).

The compression therapy used will be Class II compression stockings. The treatment offered will be foam sclerotherapy of varicose veins using either Polidocanol or Sodium Tetradecyl Sulphate (STS) with the concentration used left to the discretion of the clinician.

Group A: Participants will be asked to wear compression stockings for 1 week following foam sclerotherapy.
Group B: Participants will be provided with bandages to wear for 24 hours only, with no further compression afterwards.

Patients in both groups will be followed-up at 2 weeks and 6 months.

Intervention type



Drug names

Primary outcome measure

Pain is measured using the visual analogue scale (VAS) at baseline and daily for the first 10 days post procedure.

Secondary outcome measures

1. Quality of life is measured using EQ-5D, AVVQ and CIVIQ at baseline, 2 weeks and 6 months
2. Clinical change is assessed using the VCSS at baseline, 2 weeks and 6 months
3. Degree of phlebitis is assessed at 2 weeks and 6 months
4. Degree of skin discolouration and matting is assessed at 2 weeks and 6 months
5. Patient compliance with the intervention
6. Time taken to return to work and normal activities
7. Occlusion rates at 6 months
8. Cost effectiveness of the intervention

Overall trial start date


Overall trial end date


Reason abandoned (if study stopped)


Participant inclusion criteria

1. Adults over 18 years of age
2. Varicose veins suitable for foam sclerotherapy

Participant type


Age group




Target number of participants

Planned Sample Size: 350; UK Sample Size: 350

Participant exclusion criteria

1. Allergic to sclerosant
2. Current DVT
3. Arterial disease (ABPI<0.8)
4. Patients unable to wear compression stockings 
5. Patient who are unwilling to participate
6. Inability or unwillingness to complete questionnaires 
7. Inability to attend follow­up appointments

Recruitment start date


Recruitment end date



Countries of recruitment

United Kingdom

Trial participating centre

Charing Cross Hospital
Imperial College London Fulham Palace Road
W6 8RF
United Kingdom

Sponsor information


Imperial College London

Sponsor details

United Kingdom

Sponsor type

Hospital/treatment centre



Funder type


Funder name

Chemische Fabrik Kreussler & Co. GmbH

Alternative name(s)

Funding Body Type

Funding Body Subtype


Results and Publications

Publication and dissemination plan

The study will be presented at international meetings and will be published in peer-reviewed journals.

Intention to publish date


Participant level data

Available on request

Basic results (scientific)

Publication list

Publication citations

Additional files

Editorial Notes

02/04/2019: The condition has been changed from "Specialty: Cardiovascular disease, Primary sub-specialty: ; UKCRC code/ Disease:" to "Varicose veins" following a request from the NIHR. 05/10/2018: The following changes have been made: 1. The recruitment end date has been changed from 31/01/2019 to 31/01/2020. 2. The overall trial end date has been changed from 01/12/2017 to 31/01/2021. 3. The intention to publish date has been changed from 31/03/2018 to 30/06/2021. 4. The total target enrolment has been changed from 350 to 180. 04/10/2018: The recruitment end date has been changed from 10/01/2017 to 31/01/2019.